Advancing Towards argenx 2025
Tim Van Hauwermeiren, Chief Executive Officer and Co-Founder, argenx
Efgartigimod: Differentiation of our Anti-FcRn Fc Fragment
Hans de Haard, Chief Scientific Officer and Co-Founder, argenx
Fifth Indication: Myositis
Bas van der Woning, Research Fellow, argenx
Sixth Indication: Bullous Pemphigoid
Peter Verheesen, Research Fellow, argenx
Myositis and Bullous Pemphigoid Panel
Moderated by Albert Kovera, Global Marketing, argenx
- Rohit Aggarwal, MD, MS – University of Pittsburgh
- Russell P. Hall III, MD – Duke University
ARGX-117 Phase 1 Data | New Biology Insights for Multifocal Motor Neuropathy
Olivier Van de Steen, Medical Director, argenx
Inge Van de Walle, Principal Scientist, argenx